Search
The Importance of Drug Discovery | R&D | Boehringer Ingelheim US
Research & Development
Coliform Mastitis: the facts to know | Boehringer Ingelheim US
Click here to learn more about different management practices that can help you to improve your dairy herd's bottom line and productivity.
Our Biotherapeutic Technology Partnering Interests
Our Biotherapeutic Technology Partnering Interests
Partnering in Biotherapeutics Technologies
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
FDA approves Ofev® as first treatment for chronic fibrosing ILDs with a progressive phenotype
Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Jardiance associated with a total cost of care savings of more than 20%, according to results from an outcomes-based agreement between Boehringer Ingelheim and Highmark
Our evolved employer value proposition
Find out from a father-daughter duo how we live up to our people promise and how our company identifies itself and differentiates from other employers.
Giving Back to Those Who Serve Our Country
Giving Back to Those Who Serve Our Country
The Evolution of Biologic Medicines
For Your SweetHeart | Infographic
Biotherapeutics Modalities Infographic
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
Ofev® demonstrates consistent long-term efficacy in IPF regardless of baseline lung function
BI & Lilly to Assess Jardiance® (empagliflozin) & Heart Failure | Boehringer Ingelheim US
Read more on the 1st ever study to assess JARDIANCE in people with heart failure who have been stabilized. View ISI, PI and Med Guide.
IT at BI
Discover firsthand what IT does at BI #IdoIT
Dr. Anna Dieckmann and Dr. Lorenz Maier
Here is the story of Dr. Anna Dieckmann and Dr. Lorenz Maier's successful partnership. For more talent insights, visit our Careers Page.
Rewards and recognition
There are achievements and occasions that demand recognition. We go out of way to give employees tangible rewards and more for business milestones.
Pascal Haubert
After three months of interning with us, Pascal Haubert talks about the importance of taking responsibility, learning and mutual support.
Rafal Rybicki
Rafał Rybicki, Head of Legal and Compliance Services in the Global Business Services (GBS) Center in Wroclaw, reflects on his first year with the company.
Vienna
Vienna is a cornerstone within the company’s global R&D network, with a special focus on cancer research. On top of that, it is also a hub for biopharmaceutical development and production.
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim, Fashion Institute of Technology’s DTech Lab introduce fifth piece to award-winning design collection that raises awareness of rare disease
Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure
Boehringer Ingelheim and Lilly provide update on Jardiance® phase III exercise ability studies in chronic heart failure
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
New Type 2 Diabetes Treatment Synjardy® (empagliflozin/metformin hydrochloride) Tablets Now Available in U.S. Pharmacies
Leadership
At Boehringer Ingelheim, we recognise and celebrate strong leadership. Here’s why our people love our leadership approach.
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway
Jardiance® Recommended as Preferred SGLT2 Inhibitor for Adults with Type 2 Diabetes and Established Cardiovascular Disease in American College of Cardiology Expert Consensus Decision Pathway